An Open-label, Single-dose, 3-Period Crossover Study to Evaluate the 2-way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects

Trial Profile

An Open-label, Single-dose, 3-Period Crossover Study to Evaluate the 2-way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Sitagliptin (Primary) ; Losartan
  • Indications Diabetic nephropathies; Heart failure; Hypertension; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Aug 2012 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by Australian New Zealand Clinical Trials Registry record.
    • 05 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top